TNFRSF8 and primary cutaneous T-cell non-Hodgkin lymphoma: This has led to the current clinical trial at the University of North Carolina Lineberger Cancer Center (NCT03602157) evaluating anti-CD30 CAR T cells that co-express CCR4 for treatment of r/r HL or CD30+ cutaneous T cell lymphoma [64].